IO Biotech, Inc. (NASDAQ:IOBT – Get Free Report) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 81,600 shares, a growth of 50.3% from the February 29th total of 54,300 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 144,900 shares, the short-interest ratio is currently 0.6 days.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of IO Biotech in a research report on Wednesday, March 6th.
Check Out Our Latest Stock Analysis on IO Biotech
Insider Activity
Hedge Funds Weigh In On IO Biotech
A number of institutional investors have recently modified their holdings of IOBT. Ergoteles LLC bought a new stake in shares of IO Biotech during the 1st quarter worth $59,000. Jane Street Group LLC bought a new stake in IO Biotech during the first quarter valued at about $76,000. Renaissance Technologies LLC acquired a new stake in shares of IO Biotech in the third quarter valued at about $50,000. Citadel Advisors LLC grew its holdings in IO Biotech by 192.4% in the 3rd quarter. Citadel Advisors LLC now owns 42,180 shares of the company’s stock valued at $114,000 after buying an additional 27,754 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of IO Biotech by 18,441.9% in the fourth quarter. Bank of America Corp DE now owns 1,854,185 shares of the company’s stock worth $4,265,000 after acquiring an additional 1,844,185 shares during the last quarter. Institutional investors own 54.76% of the company’s stock.
IO Biotech Stock Performance
IO Biotech stock remained flat at $1.73 during mid-day trading on Friday. 53,557 shares of the company’s stock traded hands, compared to its average volume of 91,416. IO Biotech has a 52-week low of $0.82 and a 52-week high of $2.64. The business has a fifty day moving average price of $1.69 and a 200 day moving average price of $1.46. The firm has a market capitalization of $113.97 million, a PE ratio of -0.80 and a beta of 0.46.
IO Biotech (NASDAQ:IOBT – Get Free Report) last issued its quarterly earnings data on Tuesday, March 5th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). Analysts expect that IO Biotech will post -1.41 EPS for the current fiscal year.
IO Biotech Company Profile
IO Biotech, Inc, a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer.
See Also
- Five stocks we like better than IO Biotech
- CD Calculator: Certificate of Deposit Calculator
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How to Calculate Options Profits
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for IO Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IO Biotech and related companies with MarketBeat.com's FREE daily email newsletter.